A Confirmatory, Registrational Clinical Trial to Evaluate the Efficacy and Safety of Vincristine Sulfate LIPOSOME Injection (MARQIBO)
Latest Information Update: 12 Mar 2019
Price :
$35 *
At a glance
- Drugs Vincristine (Primary)
- Indications Haematological malignancies; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors CASI Pharmaceuticals
- 07 Mar 2019 According to a CASI Pharmaceuticals media release, the company is currently reviewing certain requirements provided by the Center for Drug Evaluation (CDE), a division of the NMPA, and upon satisfying those requirements, the company will commence this registration trial for MARQIBO.
- 07 Mar 2019 According to a CASI Pharmaceuticals media release, the National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) allowing for this registration clinical trial to evaluate the efficacy and safety of vincristine sulfate LIPOSOME injection (MARQIBO).
- 15 Sep 2017 New trial record